FIGURE 2 | Targets for treatment of immune checkpoint inhibitor-mediated colitis (IMC). In fl iximab and vedolizumab are already standard of care in steroid-refractory IMC. The other agents are currently not routinely given to patients. This image was created with BioRender.com. CTL, Cytotoxic T-lymphocyte; IFN, Interferon; IL, Interleukin; JAK, Janus kinase; Th17, T helper 17 cell; TNF, Tumor necrosis factor; Treg, regulatory